D-1537-2014 Class III Terminated
FDA drug recall D-1537-2014 was initiated by Pfizer Inc. on Jul 30, 2014 and is designated Class III. Reason for recall: Failed pH Specification: A pH result of 2.9 was obtained at the 9 month stability test interval at 25C/60%RH. The registered specification for pH is 3.0 - 7.0 The recall status is terminated (terminated Mar 22, 2017). Affected quantity: 93,800 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 20, 2014
- Initiation Date
- Jul 30, 2014
- Termination Date
- Mar 22, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 93,800 vials
Product description
Depo-Medrol (methylprednisolone acetate injectable suspension USP), 40 mg/ mL, 1 mL Single-Dose Vial, Rx only, Distributed by Pharmacia & Upjohn Co Division of Pfizer Inc, New York NY 10017 NDC 0009-3073-03 DEPO-MEDROL methylprednisolone acetate Injectable Suspension USP, 40 mg per mL, 1 mL Single-Dose Vial, Rx ONLY, Distributed by Pharmacia & Upjohn Co Division of Pfizer Inc, New York NY 10017, NOVAPLUS is a registered trademark of Novation, LLC NDC 0009-3073-23
Reason for recall
Failed pH Specification: A pH result of 2.9 was obtained at the 9 month stability test interval at 25C/60%RH. The registered specification for pH is 3.0 - 7.0
Distribution pattern
Nationwide
Code information
Lot H43272, H43265 Exp. 09/14
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1537-2014
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026